Systemic consequences of intravitreal therapies have been previously documented, as in the case of anti-VEGF agents, where reduced plasma VEGF activity has been associated with hypertension, proteinuria, and chronic kidney disease [99,100]. Here, VEGFA is linked to chronic kidney disease.